【摘要】 目的:观察升荣胶囊联合草酸铂+CF+5-FU治疗晚期大肠癌的疗效。方法:64例晚期大肠癌患者,分为治疗组(34例,升荣胶囊联合化疗)和对照组(30例,单纯化疗)观察两组疗效。结果:治疗组和对照组的临床受益率(CR+PR+SD)分别为88.2%和60.0%(P<0.05),9个月及12个月生存率分别为81.5%,74.6%和67.3%,45.8%(P<0.05)。升荣胶囊可提高细胞及体液免疫功能、杀伤肿瘤细胞,降低患者的血液高凝状态、缓解化疗药物的不良反应、改善患者的生活质量。结论:升荣胶囊联合草酸铂+CF+5-FU治疗晚期大肠癌有较好的疗效。更多还原

【Abstract】 Objective:To observe the effect of Shengrong capsule combined with L-OHP+CF+5-FU regimen in treating advanced colorectal cancer patients.Methods:Sixty four advanced colorectal cancer patients were randomly assigned to treatment group(34 patients,treated by Shengrong capsule combined with L-OHP +CF +5-FU) and control group(30 patients,treated with L-OHP + CF+5-FU regimen).The therapeutic effects of two groups were observed.Results:Clinical beneficial rates(CR+PR+SD) of treatment group and control group were 88.2% and 60.0% respectively(P<0.05),9 and 12 month survival rates were 81.5%,74.6% and 67.3%,45.8%(P<0.05).Shengrong capsule decreased blood hypercoagulability,improved cellular immune function of patients,relieved myelosuppression of chemotherapeutic agents and improved quality of life of patients.Conclusion:Shengrong capsule combined with L-OHP +CF+5-FU regimen had better effect in treatment of advanced colorectal cancer patients.更多还原